JP2011516041A - 抗ｔｙｒｐ１抗体 - Google Patents

抗ｔｙｒｐ１抗体 Download PDF

Info

Publication number
JP2011516041A
JP2011516041A JP2010550830A JP2010550830A JP2011516041A JP 2011516041 A JP2011516041 A JP 2011516041A JP 2010550830 A JP2010550830 A JP 2010550830A JP 2010550830 A JP2010550830 A JP 2010550830A JP 2011516041 A JP2011516041 A JP 2011516041A
Authority
JP
Japan
Prior art keywords
antibody
seq
antibodies
human
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010550830A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011516041A5 (https=
Inventor
シャオキアン・カン
ポール・ジェイ・バルディアス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
ImClone LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40790741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2011516041(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ImClone LLC filed Critical ImClone LLC
Publication of JP2011516041A publication Critical patent/JP2011516041A/ja
Publication of JP2011516041A5 publication Critical patent/JP2011516041A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010550830A 2008-03-12 2009-03-11 抗ｔｙｒｐ１抗体 Pending JP2011516041A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6919908P 2008-03-12 2008-03-12
US61/069,199 2008-03-12
PCT/US2009/036739 WO2009114585A1 (en) 2008-03-12 2009-03-11 Anti-tyrp1 antibodies

Publications (2)

Publication Number Publication Date
JP2011516041A true JP2011516041A (ja) 2011-05-26
JP2011516041A5 JP2011516041A5 (https=) 2014-03-06

Family

ID=40790741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010550830A Pending JP2011516041A (ja) 2008-03-12 2009-03-11 抗ｔｙｒｐ１抗体

Country Status (19)

Country Link
US (1) US7951370B2 (https=)
EP (1) EP2268672A1 (https=)
JP (1) JP2011516041A (https=)
KR (1) KR101203777B1 (https=)
CN (1) CN101970500B (https=)
AR (1) AR070821A1 (https=)
AU (1) AU2009222998B2 (https=)
BR (1) BRPI0909633A2 (https=)
CA (1) CA2718289A1 (https=)
CL (1) CL2009000567A1 (https=)
EA (1) EA019517B1 (https=)
IL (1) IL207581A0 (https=)
MX (1) MX2010010021A (https=)
NZ (1) NZ587305A (https=)
PE (1) PE20091679A1 (https=)
TW (1) TWI384997B (https=)
UA (1) UA99339C2 (https=)
WO (1) WO2009114585A1 (https=)
ZA (1) ZA201006099B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022546590A (ja) * 2019-09-06 2022-11-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんの処置のためのキメラ抗原受容体ならびに関連した方法および組成物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2167540T (lt) * 2007-06-29 2018-04-25 F. Hoffmann-La Roche Ag Sunkioji grandinė mutantė, pagerinanti imunoglobulino gamybą
SG11201606439VA (en) 2014-02-07 2016-09-29 Dong Wha Pharm Co Ltd Anticancer adjuvant composition containing rip3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting rip3 expression, and method for monitoring sensitivity of anticancer drug
DK3233907T3 (da) 2014-12-19 2021-06-07 Genmab As Bispecifikke heterodimeriske proteiner hos gnavere
RU2630647C1 (ru) * 2016-05-27 2017-09-11 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
GB201613167D0 (en) 2016-07-29 2016-09-14 Univ Southampton Cancer and b-cell related disease therapy
WO2018075586A1 (en) * 2016-10-18 2018-04-26 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof
AU2017418590A1 (en) * 2017-06-14 2020-01-16 Adicet Therapeutics, Inc. Antibodies capable of binding HLA-A2/TyrD in an HLA restricted manner and uses thereof
RU2687609C1 (ru) * 2018-05-30 2019-05-15 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Гуманизированное антитело к конформационному эпитопу сз компонента комплемента человека
PL3856775T3 (pl) 2018-09-27 2025-06-09 Autolus Limited Chimeryczny receptor antygenowy
US12371507B2 (en) 2018-11-09 2025-07-29 Beth Israel Deaconess Medical Center CDCP1 antibodies and antibody drug conjugates
SG10202105788SA (en) * 2018-12-21 2021-06-29 Hoffmann La Roche Antibodies binding to cd3
CN115515976A (zh) * 2020-03-19 2022-12-23 帝国理工学院创新有限公司 冠状病毒抗体
JP2024543257A (ja) * 2021-11-26 2024-11-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｔｙｒｐ１／抗ｃｄ３二重特異性抗体およびｔｙｒｐ１特異性抗体の併用療法
WO2025104289A1 (en) 2023-11-17 2025-05-22 Medincell S.A. Antineoplastic combinations
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508014A (ja) * 2000-05-16 2004-03-18 ボルダー　バイオテクノロジー，　インコーポレイテッド 遊離システイン残基を含有するタンパク質をリフォールディングする方法
WO2006047340A2 (en) * 2004-10-22 2006-05-04 Amgen Inc. Methods for refolding of recombinant antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798790A (en) * 1985-07-18 1989-01-17 Sloan-Kettering Institute Monoclonal antibody specific for a pigmentation associated antigen
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
ES2070172T3 (es) 1988-04-16 1995-06-01 Celltech Ltd Procedimiento para producir proteinas mediante adn recombinante.
IE910820A1 (en) 1990-03-22 1991-09-25 Sloan Kettering Inst Cancer Gp75 as a tumor vaccine for melanoma
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
AU6171196A (en) 1995-06-07 1996-12-30 Sloan-Kettering Institute For Cancer Research Therapeutic uses of ta99
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
BR9815289A (pt) * 1997-11-14 2001-12-26 Euro Celtique Sa Imunoglobulina modificada, molécula, ácidonucleico isolado, célula contendo o mesmo, animalnão-humano recombinante, composiçãofarmacêutica, composição de vacina, processospara identificar ou medir ou detectar um antìgenode câncer, um antìgeno de um agente de doençainfecciosa, um ligante, e um receptor em umaamostra a ser testada, kits para detecção de umantìgeno de câncer, de um antìgeno de um agentede doença infecciosa, de um receptor celular paraum agente de doença infecciosa, de um ligante, e deum antìgeno de câncer, processos de diagnósticoou de exame para a presença de ou umapredisposição para desenvolvimento de um câncertipificado pela presença aumentada de umantìgeno de câncer, e para a presença de umagente de doença infecciosa, processos detratamento ou de prevenção de um câncertipificado pela presença de um antìgeno de câncer,de uma doença infecciosa tipificada pela presençade um antìgeno de agente de doença infecciosa, ede uma doença causada por um agente de doençainfecciosa que se liga em um receptor celular,processos para modulação de atividade de umprimeiro membro de um par de ligação, processo deprodução de uma imunoglobulina modificada,processo de produção de um ácido nucleicocodificador de imunoglobulina modificada, e, ácidonucleico isolado

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508014A (ja) * 2000-05-16 2004-03-18 ボルダー　バイオテクノロジー，　インコーポレイテッド 遊離システイン残基を含有するタンパク質をリフォールディングする方法
WO2006047340A2 (en) * 2004-10-22 2006-05-04 Amgen Inc. Methods for refolding of recombinant antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5011011952; ＰＡＴＥＬ　ＤＩＰＡ: 'ＧＥＮＥＲＡＴＩＯＮ　ＡＮＤ　ＣＨＡＲＡＣＴＥＲＩＺＡＴＩＯＮ　ＯＦ　Ａ　ＴＨＥＲＡＰＥＵＴＩＣ　ＨＵＭＡＮ　ＡＮＴＩＢＯＤＹ　ＴＯ　ＭＥＬＡＮＯＭＡ　ＡＮＴＩＧＥＮ　ＴＹＲＰ１' ＨＵＭＡＮ　ＡＮＴＩＢＯＤＩＥＳ Ｖ１６　Ｎ３-４, 20070101, Ｐ１２７-１３６ *
JPN6013051596; Ｒｏｂｅｒｔ　Ｇ．　Ｈａｍｉｌｔｏｎ: Ｔｈｅ　Ｈｕｍａｎ　ＩｇＧ　Ｓｕｂｃｌａｓｓｅｓ , 2001, Ｃａｌｂｉｏｃｈｅｍ-Ｎｏｖａｂｉｏｃｈｅｍ　Ｃｏｒｐｏｒａｔｉｏｎ *
JPN6013051598; ＢＹ　ＧＥＲＡＬＤ　Ｍ．　ＥＤＥＬＭＡＮ，　ＢＲＵＣＥ　Ａ．　ＣＵＮＮＩＮＧＨＡＭ，　Ｗ．　ＥＩＮＡＲ　ＧＡＬＬ，ＰＡＵＬ　Ｄ．　ＧＯＴＴＬＩＥＢ，　ＵＲＳ　ＲＵＴＩＳＨＡＵＳＥＲ，　ＡＮＤ　ＭＹＲＯ: 'ＴＨＥ　ＣＯＶＡＬＥＮＴ　ＳＴＲＵＣＴＵＲＥ　ＯＦ　ＡＮ　ＥＮＴＩＲＥ　ＴＧ　ＩＭＭＵＮＯＧＬＯＢＵＬＩＮ　ＭＯＬＥＣＵＬＥ' Ｐｒｏｃｅｅｄｉｎｇｓ　ｏｆ　ｔｈｅ　Ｎａｔｉｏｎａｌ　Ａｃａｄｅｍｙ　ｏｆ　Ｓｃｉｅｎｃｅｓ　ｏｆ　ｔｈｅ　Ｕｎｉｔｅｄ　Ｓｔａｔｅｓ　ｏｆ　Ａｍｅｒｉｃａ Ｖｏｌ．　６３，&#x3000 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022546590A (ja) * 2019-09-06 2022-11-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんの処置のためのキメラ抗原受容体ならびに関連した方法および組成物
JP7820819B2 (ja) 2019-09-06 2026-02-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんの処置のためのキメラ抗原受容体ならびに関連した方法および組成物

Also Published As

Publication number Publication date
WO2009114585A1 (en) 2009-09-17
AR070821A1 (es) 2010-05-05
EP2268672A1 (en) 2011-01-05
AU2009222998B2 (en) 2013-05-23
US7951370B2 (en) 2011-05-31
BRPI0909633A2 (pt) 2015-09-22
KR101203777B1 (ko) 2012-11-21
AU2009222998A1 (en) 2009-09-17
CL2009000567A1 (es) 2010-02-26
PE20091679A1 (es) 2009-11-04
MX2010010021A (es) 2011-02-15
EA201071068A1 (ru) 2011-04-29
UA99339C2 (ru) 2012-08-10
IL207581A0 (en) 2010-12-30
TW200944232A (en) 2009-11-01
CN101970500B (zh) 2013-08-14
CA2718289A1 (en) 2009-09-17
ZA201006099B (en) 2012-01-25
KR20100113631A (ko) 2010-10-21
US20090232823A1 (en) 2009-09-17
CN101970500A (zh) 2011-02-09
NZ587305A (en) 2012-05-25
TWI384997B (zh) 2013-02-11
EA019517B1 (ru) 2014-04-30

Similar Documents

Publication Publication Date Title
KR101203777B1 (ko) 항-ｔｙｒｐ１ 항체
EP3683239B1 (en) Antibodies binding human claudin 18.2 and uses thereof
TWI402078B (zh) 抗ｃｓｆ－１ｒ抗體
US8071099B2 (en) Anti-FLT3 antibodies
AU2007324509B2 (en) Novel antiproliferation antibodies
JP2011516041A5 (https=)
JP2018526974A (ja) Ｐｄｌ−１抗体、その医薬組成物及びその使用
KR20240162588A (ko) Cd3 및 bcma에 대한 항체, 및 이로부터 제조된 이중특이적 결합 단백질
CN114907479B (zh) 抗cd112r抗体及其用途
JP7505148B2 (ja) Ｌａｇ３に結合する抗体およびその使用
JP2022502417A (ja) 抗ｏｘ４０抗体、その抗原結合フラグメント、および医薬用途
HK40090114A (en) Antibodies binding human claudin 18.2 and uses thereof
HK40029982B (en) Antibodies binding human claudin 18.2 and uses thereof
HK40089230A (zh) 药物组合物及用途
HK40078463B (zh) 一种抗claudin18.2单克隆抗体、其制备方法及用途
HK40040207A (en) Antibody binding tim-3 and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131022

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20140115

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140812